Hope shines bright for hidradenitis suppurativa treatments.

The article offers information on the annual congress of the European Academy of Dermatology and Venereology. It reports that secukinumab and the investigational drug brepocitinib reduced the effects of the chronic and painful skin condition in hidradenitis suppurativa (HS) treatment. It presents the views of Christopher Sayed, associate professor of dermatology at the University of North Carolina, on the need for alternative medication for this condition.